[{"id":"ca7e4b34-6f76-4ea3-8c6b-e39973324752","acronym":"NRG-LU003","url":"https://clinicaltrials.gov/study/NCT03737994","created_at":"2023-11-21T21:15:46.432Z","updated_at":"2025-02-25T12:37:11.248Z","phase":"Phase 2","brief_title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03737994 - NRG-LU003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" ALK positive • MET amplification • ALK rearrangement","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • MET amplification • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/25/2019","start_date":" 07/25/2019","primary_txt":" Primary completion: 07/21/2021","primary_completion_date":" 07/21/2021","study_txt":" Completion: 12/02/2025","study_completion_date":" 12/02/2025","last_update_posted":"2025-02-24"},{"id":"d9249df0-7324-4379-b412-dbfbc6b5d9e8","acronym":"NAUTIKA1","url":"https://clinicaltrials.gov/study/NCT04302025","created_at":"2021-01-18T20:51:55.005Z","updated_at":"2025-02-25T13:40:05.730Z","phase":"Phase 2","brief_title":"A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04302025 - NAUTIKA1","lead_sponsor":"Genentech, Inc.","biomarkers":" PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12","tags":["PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 03/06/2029","study_completion_date":" 03/06/2029","last_update_posted":"2025-02-21"},{"id":"bbff33d0-fbb7-447e-b61a-196b5c2984ea","acronym":"ALTA-3","url":"https://clinicaltrials.gov/study/NCT03596866","created_at":"2021-01-18T17:41:06.342Z","updated_at":"2025-02-25T14:07:13.042Z","phase":"Phase 3","brief_title":"A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer","source_id_and_acronym":"NCT03596866 - ALTA-3","lead_sponsor":"Takeda","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Alecensa (alectinib) • Alunbrig (brigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 248","initiation":"Initiation: 04/19/2019","start_date":" 04/19/2019","primary_txt":" Primary completion: 02/27/2024","primary_completion_date":" 02/27/2024","study_txt":" Completion: 09/12/2024","study_completion_date":" 09/12/2024","last_update_posted":"2025-02-19"},{"id":"137ec32f-5e52-4616-9b33-b322d2b339d9","acronym":"TAPISTRY","url":"https://clinicaltrials.gov/study/NCT04589845","created_at":"2021-04-08T16:52:35.237Z","updated_at":"2025-02-25T14:07:57.580Z","phase":"Phase 2","brief_title":"Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","source_id_and_acronym":"NCT04589845 - TAPISTRY","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Gavreto (pralsetinib) • ipatasertib (RG7440) • belvarafenib (RG6185) • idasanutlin (RG7388) • divarasib (RG6330) • Itovebi (inavolisib) • camonsertib (RP-3500)"],"overall_status":"Recruiting","enrollment":" Enrollment 920","initiation":"Initiation: 01/18/2021","start_date":" 01/18/2021","primary_txt":" Primary completion: 09/25/2032","primary_completion_date":" 09/25/2032","study_txt":" Completion: 09/25/2032","study_completion_date":" 09/25/2032","last_update_posted":"2025-02-17"},{"id":"6d9c9dc1-5735-46b5-bfc4-9aa69eeeef0c","acronym":"BFAST","url":"https://clinicaltrials.gov/study/NCT03178552","created_at":"2021-01-18T15:40:25.224Z","updated_at":"2025-02-25T15:17:28.532Z","phase":"Phase 2/3","brief_title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03178552 - BFAST","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF • TMB","pipe":"","alterations":" ","tags":["BRAF • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • carboplatin • gemcitabine • Rozlytrek (entrectinib) • docetaxel • Alecensa (alectinib) • Cotellic (cobimetinib) • pemetrexed • divarasib (RG6330)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 09/22/2017","start_date":" 09/22/2017","primary_txt":" Primary completion: 08/03/2028","primary_completion_date":" 08/03/2028","study_txt":" Completion: 08/03/2028","study_completion_date":" 08/03/2028","last_update_posted":"2025-02-12"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"a0f41c59-aa55-45a8-ab7a-26f77921a6a6","acronym":"GO42286","url":"https://clinicaltrials.gov/study/NCT04774718","created_at":"2021-03-01T14:52:34.144Z","updated_at":"2025-02-25T16:45:19.897Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors","source_id_and_acronym":"NCT04774718 - GO42286","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ALK","pipe":" | ","alterations":" ALK fusion","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alecensa (alectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 02/28/2032","study_completion_date":" 02/28/2032","last_update_posted":"2025-02-05"},{"id":"e6ddbe9a-bb3f-4f95-a33c-1e9db3a4644c","acronym":"ALINA","url":"https://clinicaltrials.gov/study/NCT03456076","created_at":"2021-01-18T17:02:25.362Z","updated_at":"2025-02-25T16:44:20.606Z","phase":"Phase 3","brief_title":"A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03456076 - ALINA","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Alecensa (alectinib) • pemetrexed • vinorelbine tartrate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 257","initiation":"Initiation: 08/16/2018","start_date":" 08/16/2018","primary_txt":" Primary completion: 06/26/2023","primary_completion_date":" 06/26/2023","study_txt":" Completion: 11/19/2026","study_completion_date":" 11/19/2026","last_update_posted":"2025-02-05"},{"id":"03fa7b60-29a0-4a44-aa05-14a8b5df45eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02091141","created_at":"2021-01-17T17:15:36.027Z","updated_at":"2025-02-25T12:26:06.921Z","phase":"Phase 2","brief_title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT02091141","lead_sponsor":"Genentech, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation","tags":["EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • erlotinib • Zelboraf (vemurafenib) • Alecensa (alectinib) • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 673","initiation":"Initiation: 04/14/2014","start_date":" 04/14/2014","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2024-07-23"},{"id":"59529bbb-f615-4981-937f-6ac29b7ec1c3","acronym":"PIKACHU","url":"https://clinicaltrials.gov/study/NCT04322890","created_at":"2021-01-18T20:56:40.742Z","updated_at":"2024-07-02T16:34:59.292Z","phase":"Phase 2","brief_title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","source_id_and_acronym":"NCT04322890 - PIKACHU","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2027","study_completion_date":" 12/24/2027","last_update_posted":"2024-06-04"},{"id":"8a3d3d41-a452-48ff-8178-8d754ba2fbf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05170204","created_at":"2021-12-27T15:54:25.891Z","updated_at":"2024-07-02T16:34:59.196Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05170204","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1 • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK fusion • ROS1 fusion","tags":["PD-L1 • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Gavreto (pralsetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 06/17/2029","primary_completion_date":" 06/17/2029","study_txt":" Completion: 04/14/2035","study_completion_date":" 04/14/2035","last_update_posted":"2024-06-04"},{"id":"3403e0c6-3612-4404-b814-9851b2605191","acronym":"","url":"https://clinicaltrials.gov/study/NCT05266846","created_at":"2022-03-04T15:53:27.020Z","updated_at":"2024-07-02T16:35:00.059Z","phase":"Phase 2","brief_title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK","source_id_and_acronym":"NCT05266846","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • cisplatin • Alecensa (alectinib) • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 05/29/2024","start_date":" 05/29/2024","primary_txt":" Primary completion: 11/16/2026","primary_completion_date":" 11/16/2026","study_txt":" Completion: 02/16/2027","study_completion_date":" 02/16/2027","last_update_posted":"2024-05-30"},{"id":"820375fa-d648-40c6-bb10-439713fd0a5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04997382","created_at":"2021-08-09T13:53:18.245Z","updated_at":"2024-07-02T16:35:01.224Z","phase":"Phase 2","brief_title":"Immunochemotherapy or Chemotherapy in ALK-rearranged 5'-ALK NSCLC","source_id_and_acronym":"NCT04997382","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • Alecensa (alectinib)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 08/17/2021","start_date":" 08/17/2021","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 01/31/2024","study_completion_date":" 01/31/2024","last_update_posted":"2024-05-24"},{"id":"5a838959-61f6-4c03-a283-91862114c15b","acronym":"DURABLE","url":"https://clinicaltrials.gov/study/NCT05987644","created_at":"2023-08-14T15:10:10.933Z","updated_at":"2024-07-02T16:35:03.520Z","phase":"Phase 1/2","brief_title":"Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements","source_id_and_acronym":"NCT05987644 - DURABLE","lead_sponsor":"Joshua Palmer","biomarkers":" PD-L1 • ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement","tags":["PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alecensa (alectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 03/07/2024","start_date":" 03/07/2024","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-05-15"},{"id":"0a02d220-b88b-4af9-9c95-4ea9bf455fe3","acronym":"ADAPT ALEC","url":"https://clinicaltrials.gov/study/NCT05525338","created_at":"2022-09-01T12:59:05.884Z","updated_at":"2024-07-02T16:35:04.248Z","phase":"Phase 4","brief_title":"Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels","source_id_and_acronym":"NCT05525338 - ADAPT ALEC","lead_sponsor":"University Medical Center Groningen","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alecensa (alectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 196","initiation":"Initiation: 03/23/2022","start_date":" 03/23/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-13"},{"id":"a6c847c7-a1bd-4b36-aa8d-0987c59a806b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04979988","created_at":"2021-07-28T19:52:27.204Z","updated_at":"2024-07-02T16:35:11.225Z","phase":"","brief_title":"Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients","source_id_and_acronym":"NCT04979988","lead_sponsor":"Pfizer","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alecensa (alectinib) • Lorbrena (lorlatinib)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 12/09/2021","primary_completion_date":" 12/09/2021","study_txt":" Completion: 12/09/2021","study_completion_date":" 12/09/2021","last_update_posted":"2024-04-05"},{"id":"f3e3da7f-1637-4eba-b20d-889e25ae40d6","acronym":"TOSS-ALK","url":"https://clinicaltrials.gov/study/NCT06339554","created_at":"2024-04-01T19:42:26.114Z","updated_at":"2024-07-02T16:35:12.078Z","phase":"","brief_title":"Alectinib-induced Endocrine Toxicity","source_id_and_acronym":"NCT06339554 - TOSS-ALK","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alecensa (alectinib)"],"overall_status":"Completed","enrollment":" Enrollment 98","initiation":"Initiation: 10/12/2018","start_date":" 10/12/2018","primary_txt":" Primary completion: 10/30/2023","primary_completion_date":" 10/30/2023","study_txt":" Completion: 10/30/2023","study_completion_date":" 10/30/2023","last_update_posted":"2024-04-01"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"251c6b33-0105-47ef-9273-5cf7a1f8bea7","acronym":"CRUKD/21/004","url":"https://clinicaltrials.gov/study/NCT05722886","created_at":"2023-02-10T15:00:24.135Z","updated_at":"2025-02-25T13:54:56.492Z","phase":"Phase 2/3","brief_title":"DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol","source_id_and_acronym":"NCT05722886 - CRUKD/21/004","lead_sponsor":"Cancer Research UK","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Perjeta (pertuzumab) • Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 825","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 10/01/2029","study_completion_date":" 10/01/2029","last_update_posted":"2024-03-20"},{"id":"14b0ab67-5750-41ae-9f57-7535c1590a2a","acronym":"GALILEO","url":"https://clinicaltrials.gov/study/NCT06234579","created_at":"2024-01-31T23:19:42.835Z","updated_at":"2024-07-02T16:35:21.449Z","phase":"","brief_title":"Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)","source_id_and_acronym":"NCT06234579 - GALILEO","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alecensa (alectinib) • Lorbrena (lorlatinib) • Alunbrig (brigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 07/12/2021","start_date":" 07/12/2021","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-01-31"},{"id":"1d2920ad-7680-4e69-b51f-ddb29e043f61","acronym":"ACT","url":"https://clinicaltrials.gov/study/NCT05238831","created_at":"2023-08-08T16:08:43.868Z","updated_at":"2025-02-25T12:28:40.109Z","phase":"Phase 1","brief_title":"SMMART Adaptive Clinical Treatment (ACT) Trial","source_id_and_acronym":"NCT05238831 - ACT","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" HR positive • HER-2 negative • EGFR positive","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • carboplatin • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • capecitabine • Piqray (alpelisib) • Zejula (niraparib) • albumin-bound paclitaxel • fulvestrant • irinotecan • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • Herzuma (trastuzumab-pkrb) • anastrozole • Erivedge (vismodegib) • Trazimera (trastuzumab-qyyp) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • EG1206A (pertuzumab biosimilar)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/30/2023","start_date":" 01/30/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-01-23"},{"id":"01d5a833-1fd0-43f1-8b08-9b99a1ad4838","acronym":"","url":"https://clinicaltrials.gov/study/NCT05296278","created_at":"2022-03-26T00:54:56.650Z","updated_at":"2024-07-02T16:35:23.954Z","phase":"Phase 2","brief_title":"Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC","source_id_and_acronym":"NCT05296278","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Alecensa (alectinib) • Lenvima (lenvatinib) • Yidafan (ivonescimab) • IBI-323 • simridarlimab (IBI-322)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 12/25/2023","start_date":" 12/25/2023","primary_txt":" Primary completion: 12/10/2025","primary_completion_date":" 12/10/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-01-10"},{"id":"38b89266-ffa0-4a06-8703-12fe3147988a","acronym":"DETERMINE","url":"https://clinicaltrials.gov/study/NCT05770037","created_at":"2023-03-15T14:02:29.643Z","updated_at":"2024-07-02T16:35:24.377Z","phase":"Phase 2/3","brief_title":"DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers","source_id_and_acronym":"NCT05770037 - DETERMINE","lead_sponsor":"Cancer Research UK","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alecensa (alectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 10/01/2029","study_completion_date":" 10/01/2029","last_update_posted":"2024-01-05"},{"id":"fa1b90d0-8c28-4ace-9d81-b327e5b1b6dc","acronym":"DARWIN II","url":"https://clinicaltrials.gov/study/NCT02314481","created_at":"2021-01-18T10:57:50.535Z","updated_at":"2024-07-02T16:35:27.240Z","phase":"Phase 2","brief_title":"Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity","source_id_and_acronym":"NCT02314481 - DARWIN II","lead_sponsor":"University College, London","biomarkers":" HER-2 • BRAF • ALK • RET","pipe":" | ","alterations":" HER-2 amplification • BRAF V600 • RET fusion • ALK fusion","tags":["HER-2 • BRAF • ALK • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • BRAF V600 • RET fusion • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • carboplatin • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/12/2017","start_date":" 05/12/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-12-04"}]